AIM To compare therapeutic responses of a vasculardisrupting-agent,combretastatin-A4-phosphate(CA4P),among hepatocellular carcinomas(HCCs)and implanted rhabdomy
AIM To evaluate the prognostic power of different molecular data in liver cancer.METHODS Cox regression screen and least absolute shrinkage and selection operat